Companies › Minghui Pharmaceutical (Hangzhou)
10 active drug programs in 19 registered trials: 11 Phase 1, 6 Phase 3, 2 Phase 2; Oncology, Ophthalmology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MHB018A Humanized anti-IGF1R antibody | IGF1R | Phase 3 | Thyroid Associated Ophthalmopathies; Thyroid Eye Disease (TED); Thyroid Eye Disease, TED | Dec 2026 |
| MH004 1.0% Ointment | – | Phase 3 | Vitiligo | Feb 2028 |
| MHB036C for Injection antibody-drug conjugate | – | Phase 2 | Advanced Breast Cancer; Advanced Solid Tumor; Advanced Lung Cancer | Apr 2027 |
| MHB039A for Injection bispecific antibody | – | Phase 2 | Advanced Breast Cancer; Advanced Solid Tumor; Advanced Lung Cancer; Advanced Malignant Solid Tumor | Apr 2028 |
| MHB009C | – | Phase 1 | Advanced Malignant Solid Tumor | Feb 2028 |
| MHB118C for Injection | – | Phase 1 | Advanced Malignant Solid Tumor | Mar 2029 |
| MHB046C | – | Phase 1 | Advanced Solid Cancer | May 2029 |
| MHB088C | – | Phase 1 | Advanced Malignant Solid Tumor | Aug 2029 |
| MHB042C | – | Phase 1 | Advanced Malignant Solid Tumor | Oct 2029 |
| MHB048C | – | Phase 1 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06989918 | MHB018A | Phase 3 | Thyroid Associated Ophthalmopathies | Ophthalmology | Dec 2026 |
| NCT06373406 | MHB036C for Injection | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2027 |
| NCT07257185 | MHB018A | Phase 3 | Thyroid Eye Disease (TED) | Ophthalmology | Aug 2027 |
| NCT07326488 | MHB009C | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Feb 2028 |
| NCT07682506 | MH004 1.0% Ointment | Phase 3 | Vitiligo | Immunology | Feb 2028 |
| NCT06345482 | MHB039A for Injection | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2028 |
| NCT07622108 | MHB018A | Phase 3 | Thyroid Eye Disease, TED | Ophthalmology | Jul 2028 |
| NCT07622121 | MHB018A | Phase 3 | Thyroid Eye Disease, TED | Ophthalmology | Jul 2028 |
| NCT07262476 | MHB018A | Phase 3 | Thyroid Eye Disease (TED) | Ophthalmology | Jan 2029 |
| NCT07045454 | MHB118C for Injection | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Mar 2029 |
| NCT07229599 | MHB036C for Injection | Phase 1 | Advanced Lung Cancer | Oncology | May 2029 |
| NCT07229599 | MHB039A for Injection | Phase 1 | Advanced Lung Cancer | Oncology | May 2029 |
| NCT06985355 | MHB046C | Phase 1 | Advanced Solid Cancer | Oncology | May 2029 |
| NCT07130383 | MHB036C for Injection | Phase 2 | Advanced Breast Cancer | Oncology | Aug 2029 |
| NCT07130383 | MHB039A for Injection | Phase 2 | Advanced Breast Cancer | Oncology | Aug 2029 |
| NCT07126665 | MHB039A for Injection | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Aug 2029 |
| NCT07126665 | MHB088C | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Aug 2029 |
| NCT07192120 | MHB048C | Phase 1 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Oncology | Oct 2029 |
| NCT07192107 | MHB042C | Phase 1 | Advanced Malignant Solid Tumor | Oncology | Oct 2029 |
Innovent Biologics (Suzhou) OHB Neonatology Amgen Candid Therapeutics Viridian Therapeutics Sling Therapeutics Zai Lab (Shanghai)
Zai Lab (Shanghai) Philogen Kyowa Kirin Stemline Therapeutics Shandong Boan Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.